Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients
Purpose: To determine the incidence of COVID 19 in a series of registered patients with non-muscle invasive bladder cancer, treated by TUR-BT and intravesical BCG. Patients and method: We analysed 127 patients with nonmuscle invasive bladder cancer, in the medium/high risk group, registered between...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bucharest College of Physicians
2020-06-01
|
| Series: | Modern Medicine |
| Subjects: | |
| Online Access: | https://medicinamoderna.ro/wp-content/uploads/2020/06/RMM_art-7.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850230207655444480 |
|---|---|
| author | Gabriel GLUCK B. RADU Angelica IONESCU A. BOAR Ioanel SINESCU |
| author_facet | Gabriel GLUCK B. RADU Angelica IONESCU A. BOAR Ioanel SINESCU |
| author_sort | Gabriel GLUCK |
| collection | DOAJ |
| description | Purpose: To determine the incidence of COVID 19 in a series of registered patients with non-muscle invasive bladder cancer, treated by TUR-BT and intravesical BCG. Patients and method: We analysed 127 patients with nonmuscle invasive bladder cancer, in the medium/high risk group, registered between 2001-2020. The patients and families have been contacted by phone. In this interval, 32 patients deceased (cardiovascular pathologies, non-urologic neoplasia, tumour progression), 95 patients are still alive, 24 women and 71 men. The average age was 61.7 (16-86), the majority being over 50, included in the high-risk group for COVID-19. The patients were resected endoscopically and received a cytostatic instillation within the fi rst 6 hours. Reresection of the tumour bed was practiced in pT1 patients. The adjuvant treatment with BCG was used in the induction form at each relapse and maintenance
(22 patients), respectively. Until 2005, we used the local strain (Cantacuzino Clinical Institute), after that, the strain
from Bulgaria (Calgevax) and Medac (Germany). Results: 95 patients are still alive. Tumour relapses were registered in 34 patients. 3 patients registered tumour progression, resolved through radical cystectomy (2) and irradiation. In 3 cases, upper tract urothelial tumours were registered (nephroureterectomy with perimeatic cystectomy). 63 patients underwent induction treatment, while 22 underwent maintenance treatment. Complications: Intolerance to BCG in 4 patients, BCG cystitis in 5 patients, arthritis in 1 patient, septic status in 2 patients. In the analysed batch of patients, no COVID-19 cases have been registered. Conclusions: It appears that the intravesical administration of BCG represents an immunologic booster (confirmable through PPD), resulting in a reduction of the COVID-19 infection incidence. |
| format | Article |
| id | doaj-art-e0c7eda94b134ec88274a070e0155e2a |
| institution | OA Journals |
| issn | 1223-0472 2360-2473 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Bucharest College of Physicians |
| record_format | Article |
| series | Modern Medicine |
| spelling | doaj-art-e0c7eda94b134ec88274a070e0155e2a2025-08-20T02:03:57ZengBucharest College of PhysiciansModern Medicine1223-04722360-24732020-06-01272103106https://doi.org/10.31689/rmm.2020.27.2.103Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC PatientsGabriel GLUCK0B. RADU1Angelica IONESCU2A. BOAR3Ioanel SINESCU4Clinic of Urology and Renal Transplantation, Fundeni Hospital, Bucharest, RomaniaClinic of Urology and Renal Transplantation, Fundeni Hospital, Bucharest, RomaniaClinic of Urology and Renal Transplantation, Fundeni Hospital, Bucharest, RomaniaClinic of Urology and Renal Transplantation, Fundeni Hospital, Bucharest, RomaniaClinic of Urology and Renal Transplantation, Fundeni Hospital, Bucharest, RomaniaPurpose: To determine the incidence of COVID 19 in a series of registered patients with non-muscle invasive bladder cancer, treated by TUR-BT and intravesical BCG. Patients and method: We analysed 127 patients with nonmuscle invasive bladder cancer, in the medium/high risk group, registered between 2001-2020. The patients and families have been contacted by phone. In this interval, 32 patients deceased (cardiovascular pathologies, non-urologic neoplasia, tumour progression), 95 patients are still alive, 24 women and 71 men. The average age was 61.7 (16-86), the majority being over 50, included in the high-risk group for COVID-19. The patients were resected endoscopically and received a cytostatic instillation within the fi rst 6 hours. Reresection of the tumour bed was practiced in pT1 patients. The adjuvant treatment with BCG was used in the induction form at each relapse and maintenance (22 patients), respectively. Until 2005, we used the local strain (Cantacuzino Clinical Institute), after that, the strain from Bulgaria (Calgevax) and Medac (Germany). Results: 95 patients are still alive. Tumour relapses were registered in 34 patients. 3 patients registered tumour progression, resolved through radical cystectomy (2) and irradiation. In 3 cases, upper tract urothelial tumours were registered (nephroureterectomy with perimeatic cystectomy). 63 patients underwent induction treatment, while 22 underwent maintenance treatment. Complications: Intolerance to BCG in 4 patients, BCG cystitis in 5 patients, arthritis in 1 patient, septic status in 2 patients. In the analysed batch of patients, no COVID-19 cases have been registered. Conclusions: It appears that the intravesical administration of BCG represents an immunologic booster (confirmable through PPD), resulting in a reduction of the COVID-19 infection incidence.https://medicinamoderna.ro/wp-content/uploads/2020/06/RMM_art-7.pdfcovid-19bladder cancerbcg |
| spellingShingle | Gabriel GLUCK B. RADU Angelica IONESCU A. BOAR Ioanel SINESCU Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients Modern Medicine covid-19 bladder cancer bcg |
| title | Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients |
| title_full | Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients |
| title_fullStr | Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients |
| title_full_unstemmed | Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients |
| title_short | Intravesical BCG: Possible Protective Impact Against COVID-19 in NMIBC Patients |
| title_sort | intravesical bcg possible protective impact against covid 19 in nmibc patients |
| topic | covid-19 bladder cancer bcg |
| url | https://medicinamoderna.ro/wp-content/uploads/2020/06/RMM_art-7.pdf |
| work_keys_str_mv | AT gabrielgluck intravesicalbcgpossibleprotectiveimpactagainstcovid19innmibcpatients AT bradu intravesicalbcgpossibleprotectiveimpactagainstcovid19innmibcpatients AT angelicaionescu intravesicalbcgpossibleprotectiveimpactagainstcovid19innmibcpatients AT aboar intravesicalbcgpossibleprotectiveimpactagainstcovid19innmibcpatients AT ioanelsinescu intravesicalbcgpossibleprotectiveimpactagainstcovid19innmibcpatients |